Ensysce Biosciences (ENSC) Deferred Taxes (2019 - 2021)

Ensysce Biosciences (ENSC) posted quarterly Deferred Taxes of -$61278.0 for Q1 2021, down 586.97% quarter-over-quarter from -$8920.0 in Q4 2019.

Ensysce Biosciences (ENSC) Deferred Taxes (2019 - 2021) Analysis & Trends

Ensysce Biosciences (ENSC) has reported Deferred Taxes for 2 consecutive years, with -$61278.0 the latest figure, recorded in Q1 2021.

In Q1 2021, Deferred Taxes changed N/A year-over-year to -$61278.0; the TTM figure through Mar 2021 stood at -$61168.0 (changed N/A YoY), while the FY2019 annual figure was -$1764.0, down 200.0% from the prior year.
Deferred Taxes retreated to -$61278.0 in Q1 2021 per ENSC's latest filing, from -$8920.0 in the prior quarter.
Across five years, Deferred Taxes topped out at $13124.0 in Q2 2019 and bottomed at -$61278.0 in Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Deferred Taxes (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-69.70 Mn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	194.40 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	2.66 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Ensysce Biosciences	942,649.19	-3.37 Mn	-	-

Download Data